Absci opened lower at $9.39, compared with its previous close of $10.12. In the last trading session, the stock traded between $8.96 and $9.94. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Absci is now worth
$ 70.57
Resulting in a loss of
$ 29.43 (29.43%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
88.89%
Hold
11.11%
Sell
0%
Markets Today
Today's Change
$-0.97 (-9.62%)
Day High
$9.94
Day Low
$8.96
Day Open
$9.39
Prev Close
$10.12
Volume
44,28,139
1W Return
-12.85%
1M Return
-5.30%
3M Return
-2.71%
6M Return
58.24%
1Y Return
165.10%
Fundamentals
Market Cap ($ Mn)
1,570
PE Ratio
-
PB Ratio
6.08
PEG Ratio
-
ROE
-60.55%
ROCE
-58.77%
EPS (TTM)
$-0.19
Investment Returns
1 Week
-12.85%
1 Month
-5.30%
3 Months
-2.71%
6 Months
58.24%
9 Months
251.77%
Financials
Quarterly
All values in $ Mn
0.7
Dec 24
1.2
Mar 25
0.6
Jun 25
0.4
Sep 25
0.7
Dec 25
0.3
Jun 26
Updates
15Jul
Absci to report Q2FY26 results on August 11, 2026
Absci Corporation will release its Q2FY26 financial results on August 11, 2026, followed by a conference call to discuss developments and outlook.
4mo ago
24Jun
Absci raises $100M to fund ABS-201 after positive Phase 1 data
Absci Corporation announced the pricing of a $100 million underwritten public offering of 13.5 million shares at $7.41 per share to advance its ABS-201 program for androgenetic alopecia and endometriosis. The company reported positive interim Phase 1 data indicating a favorable safety and pharmacokinetic profile, with a half-life of at least 65 days, and plans to initiate a Phase 2 trial for endometriosis later this year.
4mo ago
24Jun
Absci reports positive Phase 1 data for ABS-201 with 65-day half-life
Absci Corporation reported positive interim Phase 1 data for ABS-201, an investigational anti-prolactin receptor antibody, demonstrating favorable safety and a half-life of at least 65 days. The study has advanced to multiple ascending doses in participants with androgenetic alopecia, with interim proof-of-concept data expected in the second half of 2026.
